2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2264

Low Educational Attainment Is Associated with Poor Patient Status in Rheumatoid Arthritis (RA) or Osteoarthritis (OA) at the Initial Rheumatology Visit, with Remarkably Similar Patterns in Either Diagnosis
Abstract Number: 2265

Survey on Gout-Related Knowledge and Perception in Inpatient Setting on Hospitalized Patients with Gout
Abstract Number: 2266

Patient Knowledge, Attitudes, and Beliefs Regarding Biologic Therapies in Ankylosing Spondylitis (AS): Insights from a Large-Scale Analysis of Social Media Platforms
Abstract Number: 2267

Health Related Quality of Life in Lupus: Self-Management- a Modifiable Predictor
Abstract Number: 2268

Patient Perspectives from a Qualitative Study Predict Non-Adherence in Rheumatoid Arthritis
Abstract Number: 2269

The Meaningful Patient Engagement in Research Framework – an Empirically Based Conceptual Framework
Abstract Number: 2270

Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis
Abstract Number: 2271

Safety of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Abstract Number: 2272

Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry
Abstract Number: 2273

An Open-Label Extension Study to Assess the Long-Term Safety of Etanercept in Pediatric Patients with Extended Oligo, Enthesitis Related, and Psoriatic Juvenile Idiopathic Arthritis: 6-Year Data from the Clipper Studies
Abstract Number: 2274

Risk of Serious Events, Serious Infections, Uveitis, Crohn’s Disease, Colitis and Malignancies in Patients with Juvenile Idiopathic Arthritis on Continuous Treatment with Etanercept over Time: A Report from a Biologics Registry
Abstract Number: 2275

Factors Related to Sustained Discontinuation of Medications for Well-Controlled JIA in the Childhood Arthritis & Rheumatology Research Alliance Registry
Abstract Number: 2276

Etanercept (Enbrel®) Treatment Retention in the Sub-Population of Pediatric Patients from a Retrospective Cohort Study Using Canadian Claims-Level Data
Abstract Number: 2277

Safety of Biologic Therapies for the Treatment of Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
Abstract Number: 2278

Biologic Switching Among JIA Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].